文拉法辛缓释剂与米氮平治疗难治性抑郁症的对照研究

目的:探讨文拉法辛缓释剂与米氮平治疗难治性抑郁症(TRD)的疗效、安全性及不良反应。方法:对68例TRD病人以简单随机抽样方法分成2组,分别给予文拉法辛与米氮平治疗8 wk,用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床疗效总评量表病情严重程度(CGI-SI)评定疗效。结果:文拉法辛组治疗剂量为(196±s 48)mg·d~(-1),显效时间(8±3)d,有效率68%,米氮平组分别为(32±11)mg·d~(-1)、(12±6)d、65%。2组疗效量表评定结果均较治疗前有显著下降,特别是文拉法辛组wk 1和wk 4的HAMA减分率为(33±3)%和(50±3)%,米氮平组为(14±3)%和(31.0±2.3)%,前者下降更为明显。结论:文拉法辛缓释剂和米氮平治疗TRD疗效均较好、安全性高、不良反应少,文拉法辛缓释剂起效更快速,其抗焦虑作用更快、更佳。

Venlafaxine extended release and mirtazapine in patients with treatment resistant depression

AIM:To study the efficacy,safety and adverse reactions of venlafaxine extended release and mirtazapine in patients with treatment resistant depression (TRD).METHODS:Sixty-eight patients with TRD were randomized into two groups and were given venlafaxine or mirtazapine for 8 weeks.The efficacy were assessed by Hamilton depression scale (HAMD),Hamilton anxiety scale (HAMA) and clinical global impression scale-severity of illness (CGI-SI).RESULTS:The average dose of venlafaxine was ( 196±s 48) mg·d~(-1), the average effective time was (8±3) d,and the effective rate was 68 %.The average dose of mirtazapine was (32±11) mg·d~(-1),the average effective time was (12±6) d,and the effective rate was 65 %.The scores after treatment were significantly decreased in both groups.The scores of HAMA were (33±3) % (wk 1) and (50±3) % (wk 4) in venlafaxine group,(14±3) % and (31.0±2.3) % in mirtazapine group.There was significant difference between two groups.CONCLUSION:Venlafaxine extended release and mirtazapine are both equally effective and safe in TRD with less adverse reactions.However,venlafaxine extended release is faster to take effect than mirtazapine.